Angiogenesis inhibitors

Details Angiogenesis inhibitors Angiogenesis inhibitors

2007-01-23

2007-01-23

Kim, Vickie (Department: 1618)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Biocides; animal or insect repellents or attractants

C424S406000

Reexamination Certificate

active

10147445

ABSTRACT:
A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula:Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, or R1and R2together, R3and R4together, or R5and R6together are O(CH2)mO, in which each of R and R′, independently, is H or C1˜C6alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.

REFERENCES:
patent: 5574168 (1996-11-01), Kuo et al.
patent: 6162819 (2000-12-01), Schindler et al.
patent: 6284763 (2001-09-01), Adams et al.
patent: 6458797 (2002-10-01), Adams et al.
patent: 2002/0103454 (2002-08-01), Sackner et al.
patent: 2003/0171403 (2003-09-01), Garthwaite et al.
patent: 2003/0186996 (2003-10-01), Teng et al.
patent: 2005/0119278 (2005-06-01), Teng et al.
patent: 2002-080367 (2002-03-01), None
patent: 2001-0099431 (2001-11-01), None
patent: WO-01/2369 (2001-01-01), None
patent: WO-01/53268 (2001-07-01), None
patent: WO 01/54680 (2001-08-01), None
patent: WO 01/54771 (2001-08-01), None
patent: WO-02/10137 (2002-02-01), None
patent: WO-2005/030121 (2005-04-01), None
Tulis et al., YC-1, a benzyl indazole derivative, stimulates vascular cGMP . . . , Database CAPLUS, AN2000:884445, abstract, Biochemical and Biophysical Research Communications, 2000, vol. 279(2), pp. 646-652.
Becker et al., The vasodilator-stimulated phophoprotein . . . , Database CAPLUS AN2000:158699, abstract, Journal of Cadiovascular Pharmacology, 2000, vol. 35(3), pp. 390-397.
S. L. Pan, et al.Investigation of YC-1-Mediated Anti-Angiogenic Activity.17thJoint Annual Conference of Biomedical Sciences, Taipei, Taiwan. Mar. 23-24, 2002.
Database CAPLUS, Institute of Cardiavascular and Arteriosclerosis Research, (Wuppertal, Germany), AN2000:158699, Becker et al., The vasodilator-stimulated phosphoprotein(VASP): target of YC-1 and nitric oxide effects in human and rat platelets, abstract only, Journal of Cardiovascular Pharmacology, 2000, vol. 35, (3), pp. 390-397.
Chun et al., “Inhibitory Effect of YC-1 on the Hypoxic Induction of Erythropoietin and Vascular Endothelial Growth Factor in Hep3B Cells”, Biochemical Pharmacology 61:947-964, 2001.
First Amended Complaint filed Nov. 8, 2005, in the U.S. District Court, Central District of California (Western Division—Los Angeles), Case No. 2.05-cv-07976-DDP-MAN, entitled “HIF Bio Inc et al v. Yung Shin Pharmaceuticals Industrial Co Ltd et al”, (101 pages).
U.S. District Court, Central District of California (Western Division—Los Angeles), Civil Docket Sheet for Case No. 2:05-cv-07976-DDP-MAN, entitled “HIF Bio Inc et al v. Yung Shin Pharmaceuticals Industrial Co Ltd et al”, filed Nov. 8, 2005 (9 pages).
European Search Report dated Feb. 3, 2006, Application No. 05291767.1-2123; France (8 pages).
Notification of the First Office Action, issued Jan. 20, 2006, during the prosecution of Chinese Application No. 03807442.7 (with English translation) (7 pages).

Affiliated with

Also associated with

Rating

Angiogenesis inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Angiogenesis inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenesis inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3756054